UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

(THE CONVERSATION) About 5.5 million Americans live with dementia, requiring US$53 billion in annual medical spending on doctor visits, hospitalizations, medications, home health aides and nursing ...

Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug ...

Leqembi (lecanemab-irmb) has potential interactions with other medications. These interactions could cause harmful effects. An interaction can occur because one substance causes another substance ...

The benefits from Eli Lilly’s Kisulna (donanemab) remain too small to justify the additional cost to the National Health Service (NHS), said the UK health technology assessor the National Institute ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

The National Institute for Health and Care Excellence (NICE) has maintained its decision not to recommend two treatments for Alzheimer’s disease on the NHS, after concluding that they still do not ...